Copyright
©The Author(s) 2022.
World J Gastrointest Oncol. Apr 15, 2022; 14(4): 765-793
Published online Apr 15, 2022. doi: 10.4251/wjgo.v14.i4.765
Published online Apr 15, 2022. doi: 10.4251/wjgo.v14.i4.765
First author | Parameters employed | AI classifier | Sizes of the training/validation sets | Outcomes | Performance | Ref. | |
1 | Wang J | Genetic and epigenetic biomarkers | Several | 137 HCC and 431 non-HCC patients | HCC screening | 0.910-0.9501,2, 0.897-0.9381,3, 75.0-91.52,4, 66.4-90.63,4, 1.0-88.82,5, 0.5-87.93,5 | [47] |
2 | Nam JY | Laboratory results, clinicopathological parameters | DNN | 424/3163 patients | HCC development in HBV cirrhosis | 0.7191,2, 0.7821,3 | [48] |
3 | Xia Q | Long non-coding RNAs | Several | 38 healthy samples, 45 chronic HBV patients, 46 liver cirrhosis, and 46 HCC patients | HCC development in HBV cirrhosis | 71.1-89.53,6 | [49] |
4 | Chen S | HBV reverse transcriptase gene sequencing | RF, SVM, KNN | 307 chronic HBV patients (202/105), 237 HCC patients (159/78) | HCC development in HBV cirrhosis | RF: 0.902-0.9031,2, 0.903-0.9431,3, SVM: 0.879-0.9241,2, 0.727-0.8581,3, KNN: 0.680-0.7371,2, 0.734-0.7471,3 | [50] |
5 | Hashem S | Laboratory results, clinicopathological parameters | Several | 3099 chronic HCV patients1324 HCC patients | HCC development in HCV cirrhosis | 93.2-95.63,6, 0.955-0.9901,3, 86.3-91.83,4, 93.9-97.33,5 | [51] |
6 | Audureau E | Laboratory results, clinicopathological parameters | Several | 836/6687 | HCC development in HCV cirrhosis | 0.633-0.8071,2, 0.623-0.7151,7 | [52] |
7 | Ioannou GN | Clinical/laboratory data extracted directly from electronic health records | DNN | 48151 patients with HCV-related cirrhosis (training:test = 9:1) | HCC development in HCV cirrhosis | 0.759-0.8061,3 | [53] |
8 | Singal AG | Laboratory results, clinicopathological parameters | RF | 442/10507 | HCC development in cirrhosis | 0.711,2, 0.641,7 | [54] |
- Citation: Christou CD, Tsoulfas G. Role of three-dimensional printing and artificial intelligence in the management of hepatocellular carcinoma: Challenges and opportunities. World J Gastrointest Oncol 2022; 14(4): 765-793
- URL: https://www.wjgnet.com/1948-5204/full/v14/i4/765.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i4.765